Antigen Background The CD4 molecule (T4) is a single chain transmembrane glycoprotein with a molecular weight of 59 kD. The CD4 antigen is expressed on a T cell subset (helper/inducer) representing 45% of peripheral blood lymphocytes and at a lower level on monocytes and germinal center macrophages. Most cases of cutaneous T cell lymphoma, including mycosis fungoides, express the CD4 antigen and HTLV-1 associated adult T cell leukemia/lymphoma is...

1ml NCL-L-CD4-368

0.5ml NCL-L-CD4-368

7ml CD4 (4B12) Bond RTU Primary

Antigen Background The CD45RO molecule, a 180 kD isoform of CD45, is reported to be expressed on 48% of peripheral blood T lymphocytes, 37% of CD4 positive lymphocytes, 80% of thymocytes and on the majority of T cell malignancies. Monocytes and granulocytes show surface expression of the antigen whereas tissue macrophages exhibit cytoplasmic expression. Disclaimer CD45RO is recommended for the detection of specific antigens of interest in normal ...

Antigen BackgroundCTLA-4, T-cell co-receptor cytotoxic T-cell antigen-4 (CTLA-4, CD152) is a critical inhibitory regulator of T-cell immunity. CTLA-4 is expressed almost exclusively on CD4+ and CD8+ T-cells and is crucial in the maintenance of T-cell homeostasis. Expression is induced on activated T-cells, with marginal expression on resting cells. The role of CTLA-4 in regulation of T-cell activity in the tumour microenvironment indicates a pote...

It’s Time for TIME Alexander “Sandy” Borowsky Professor of Pathology and Laboratory Medicine Center for Immunology and Infectious Diseases Disclosures Bristol-Meyers Squibb/Celgene: Funded through Investigator Sponsored Research (ISR) program. Discovery proposal. Leica/Aperio: Funded to run the “Genesis” study for primary diagnosis from whole slide images. Honorarium for this presentation. Histolix: Slide-free histology (Levenson and Fereidouni). Pfizer: Pfizer Protocol A9001502, Treatment Resistance Following Therapies (TRANSLATE) site PI. Agenda: In contracting to join the “FLEX” registry. None of these has actually paid me, only funding for the research projects. Objectives • Introduction into the complexity of the TIME and the development of new cancer treatments though di...

Introduction to immuno oncology 1. Introduction to Immuno-Oncology Michael Bates, MD Oncology Strategy, Medical and Scientific Affairs Cepheid Sunnyvale, CA Cepheid and Leica Biosystems are Danaher Companies 2. Overview • History of Immuno-Oncology • Types of Immunotherapy • Immunomodulatory agents • Personalized Cancer Vaccines • CAR-T cell therapy • Immune Checkpoint Inhibitors • Focus: Immune Checkpoint Biomarkers 3. Evolution of Cancer Immunotherapy • William Coley – 1890s surgeon • Coley’s toxin… • BCG, IFN-alpha, IL-2 • IL-2 applications in melanoma and RCC proved that advanced metastatic cancers can be controlled in some patients by stimulating T cells with cytokines • Critical development • CTLA-4 shown to be inhibitory for T cell responses by James Allison and Jeff Blu...

Immunohistochemistry (IHC) detects proteins of interest within whole tissue sections, keeping cellular organization intact.